Founder’s Note
I founded RiboEdge Biotech with a single question in mind:
What if Africa led the future of global antiviral innovation?
Too many of our diseases and lives are left behind because our pathogens aren’t profitable. But that ends here. At RiboEdge Biotech, we’re not waiting for solutions to arrive, we’re creating them. Rooted in African science, driven by global biotech tools, and powered by urgency, our work starts with RNA-based solutions for Crimean-Congo Hemorrhagic Fever and will expand from there.
This is personal for me. Not just as a scientist, but as someone who believes in the power of locally led solutions. I see a future where Africa no longer asks for a seat at the biotech table, we build the damn table ourselves.
— Kamogelo Chauke
Founder
About Us
RiboEdge Biotech is a Johannesburg-based biotechnology startup pioneering RNA-based therapeutics for neglected infectious diseases in Africa starting with Crimean-Congo Hemorrhagic Fever (CCHF).
With a focus on siRNA drug design, we are developing precision therapies that silence key viral genes of CCHFV, a deadly BSL-4 pathogen endemic in parts of Africa, Europe, and Asia.
We combine bioinformatics, RNA biology, and African disease insights to deliver scalable, data-driven therapeutic solutions that address the continent’s most overlooked viral threats.
Our long-term vision is to build Africa’s first RNA therapeutics powerhouse, one that translates world-class science into real-world public health impact.
Get in Touch / Stay Connected
Want to collaborate, advise, or learn more about our work?
We're open to conversations, partnerships, and opportunities to grow African biotech from the inside out.
Create Your Own Website With Webador